Skip to content
Study details
Enrolling now

Anti Inflammatory Lipid Mediators in Asthma

University of Colorado, Denver
NCT IDNCT03762395ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

60

Study length

about 7 years

Ages

18–65

Locations

1 site in CO

About this study

This trial is testing a treatment called CXA-10 to see if it helps people with asthma and obesity. The goal is to determine if CXA-10 reduces inflammation in the lungs, which can worsen asthma symptoms.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take CXA-10
  • 2.Take Matching Placebo
PhasePhase 2
Primary goalChanges in pre-bronchodilator FEV1 per spirometry

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low12%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Endpoints

Primary: Changes in pre-bronchodilator FEV1 per spirometry

Body systems

Endocrinology, Respiratory